Skip to main content

NVO · Novo Nordisk A S · Webcasts, Transcripts & Audio

Track NVO — free
$41.63 +0.98 (+2.41%) At close · Nov 13 Play latest call Q3 2026 earnings call transcript
Market Cap
$183.52B
Shares
4.41B
Volume · Nov 13 11.71M Avg daily vol (3M) 12.34M

Novo Nordisk A S Webcasts

Earnings calls, investor updates, investor days and conferences for Novo Nordisk A S (NVO), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Earnings call
FY26 · Q4
2027-02-03
Novo Nordisk A S (NVO) Q4 2026 Earnings Call
Scheduled
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY26 · Q3
2026-11-04
Novo Nordisk A S (NVO) Q3 2026 Earnings Call Transcript
Confident tone Financial performance and guidance Oral GLP-1 launches Pipeline and clinical milestones
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q2
2026-08-05
Novo Nordisk A S (NVO) Q2 2026 Earnings Call Transcript
Positive tone Wegovy pill (WagoviPill/VigoviPill) launch and uptake U.S. pricing pressure and channel mix International operations and Wegovy pill ex-U.S. rollout
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-06
Novo Nordisk A S (NVO) Q1 2026 Earnings Call Transcript
Positive tone 2026 financial guidance and operating profit Cost transformation, headcount and SG&A discipline Intellectual property defense and loss of exclusivity
Results not yet reported
Audio Transcript Slides 8-K10-Q
Annual General Meeting
Investor event
2026-03-26
Novo Nordisk A S (NVO) March 26, 2026 Annual General Meeting
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q4
2025-12-31
Date not confirmed
Novo Nordisk A S (NVO) Q4 2025 Earnings Call Transcript
Positive tone Wegovy pill launch Obesity care growth Pipeline readouts and approvals
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-09-30
Date not confirmed
Novo Nordisk A S (NVO) Q3 2025 Earnings Call Transcript
Balanced tone Strategic focus on diabetes and obesity GLP-1 franchise performance (Ozempic, Wegovy, Rybelsus) Business development and M&A (Akero, Metsera)
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-06-30
Date not confirmed
Novo Nordisk A S (NVO) Q2 2025 Earnings Call Transcript
Cautious tone Obesity care / Wegovy Pipeline and R&D GLP-1 diabetes / Ozempic
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-03-31
Date not confirmed
Novo Nordisk A S (NVO) Q1 2025 Earnings Call Transcript
Positive tone GLP-1 volume leadership and patient growth Wegovy U.S. obesity growth Compounding impact and guidance cut
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q3
2024-09-30
Date not confirmed
Novo Nordisk A S (NVO) Q3 2024 Earnings Call Transcript
Confident tone GLP-1 scaling and patient reach Pipeline and R&D readouts Obesity care growth
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-06-30
Date not confirmed
Novo Nordisk A S (NVO) Q2 2024 Earnings Call Transcript
Confident tone GLP-1 franchise (Ozempic, Wegovy, Rybelsus) Obesity Care and Wegovy supply Sustainability and patients reached
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-03-31
Date not confirmed
Novo Nordisk A S (NVO) Q1 2024 Earnings Call Transcript
Confident tone Obesity supply expansion (Wegovy) R&D pipeline and readouts GLP-1 sales momentum
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2023-12-31
Date not confirmed
Novo Nordisk A S (NVO) Q4 2023 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-09-30
Date not confirmed
Novo Nordisk A S (NVO) Q3 2023 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-06-30
Date not confirmed
Novo Nordisk A S (NVO) Q2 2023 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-03-31
Date not confirmed
Novo Nordisk A S (NVO) Q1 2023 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2022-12-31
Date not confirmed
Novo Nordisk A S (NVO) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-09-30
Date not confirmed
Novo Nordisk A S (NVO) Q3 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-06-30
Date not confirmed
Novo Nordisk A S (NVO) Q2 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-03-31
Date not confirmed
Novo Nordisk A S (NVO) Q1 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2021-12-31
Date not confirmed
Novo Nordisk A S (NVO) Q4 2021 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-09-30
Date not confirmed
Novo Nordisk A S (NVO) Q3 2021 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-06-30
Date not confirmed
Novo Nordisk A S (NVO) Q2 2021 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-03-31
Date not confirmed
Novo Nordisk A S (NVO) Q1 2021 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2020-12-31
Date not confirmed
Novo Nordisk A S (NVO) Q4 2020 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-09-30
Date not confirmed
Novo Nordisk A S (NVO) Q3 2020 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-06-30
Date not confirmed
Novo Nordisk A S (NVO) Q2 2020 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-03-31
Date not confirmed
Novo Nordisk A S (NVO) Q1 2020 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Showing 1–28 of 28 webcasts
Key facts CIK 353278 CUSIP 670100205 13F (30d) 960 filings 885 filers Visit website Investor relations